Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:51:38.376Z.
Calculation as of: 2026-10-06T15:51:38.376Z.
Quote observation: 2026-10-06T15:44:51.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bcc3f1894ec499320e43c54a24f2662d6ad9e54feca4b92c79248349e67b8166
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2021-03-31.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$4.02M
EV/Sales Ratio
N/A
TTM Avg
2126.93x
3Y Avg
1896.72x
5Y Avg
1896.72x
Market Cap
$4.22M
EV/Sales Ratio
N/A
TTM Avg
15.56x
3Y Avg
15.94x
5Y Avg
15.35x
Market Cap
$4.05M
EV/Sales Ratio
N/A
TTM Avg
0.35x
3Y Avg
5.55x
5Y Avg
4.43x
Market Cap
$4.33M
EV/Sales Ratio
12.70x
TTM Avg
5.50x
3Y Avg
15.32x
5Y Avg
34.36x
Market Cap
$4.40M
EV/Sales Ratio
N/A
TTM Avg
3707.31x
3Y Avg
3707.31x
5Y Avg
3707.31x
Market Cap
$3.56M
EV/Sales Ratio
N/A
TTM Avg
5.13x
3Y Avg
110.83x
5Y Avg
110.83x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.07M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.02M | N/A | 2126.93x | 1896.72x | 1896.72x |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.22M | N/A | 15.56x | 15.94x | 15.35x |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.05M | N/A | 0.35x | 5.55x | 4.43x |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.28M | 0.15x | 0.77x | 0.77x | 0.77x |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.33M | 12.70x | 5.50x | 15.32x | 34.36x |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.40M | N/A | 3707.31x | 3707.31x | 3707.31x |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.50M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.56M | N/A | 5.13x | 110.83x | 110.83x |
| Nexalin Technology, Inc. (NXL)vs › | $3.60M | 11.93x | 51.17x | 75.53x | 61.28x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2021-03-31 | 53725.89x |
| 2021-03-30 | 52104.92x |
| 2021-03-29 | 54652.16x |
| 2021-03-26 | 51062.87x |
| 2021-03-25 | 50715.52x |
| 2021-03-24 | 50020.81x |
| 2021-03-23 | 57662.54x |
| 2021-03-22 | 59630.86x |
| 2021-03-19 | 58125.67x |
| 2021-03-18 | 61483.40x |
| 2021-03-17 | 62872.80x |
| 2021-03-16 | 63104.37x |
| 2021-03-15 | 67388.36x |
| 2021-03-12 | 64377.99x |
| 2021-03-11 | 68314.63x |
| 2021-03-10 | 60672.91x |
| 2021-03-09 | 59978.21x |
| 2021-03-08 | 60788.70x |
| 2021-03-05 | 57905.68x |
| 2021-03-04 | 61367.61x |
| 2021-03-03 | 67156.80x |
| 2021-03-02 | 69240.90x |
| 2021-03-01 | 71788.14x |
| 2021-02-26 | 70746.09x |
| 2021-02-25 | 70861.87x |
| 2021-02-24 | 79777.22x |
| 2021-02-23 | 72482.85x |
| 2021-02-22 | 75261.65x |
| 2021-02-19 | 81513.97x |
| 2021-02-18 | 85103.27x |
| 2021-02-17 | 86376.89x |
| 2021-02-16 | 88576.78x |
| 2021-02-12 | 90660.88x |
| 2021-02-11 | 87997.86x |
